The mTOR Inhibitor Temsirolimus Added to Rituximab Combined With Dexamethasone, Cytarabine, and Cisplatinum (R-DHAP) for the Treatment of Patients With Relapsed or Refractory DLBCL – Results From the Phase-II STORM Trial

Benutzer: Gast

Titel:: The mTOR Inhibitor Temsirolimus Added to Rituximab Combined With Dexamethasone, Cytarabine, and Cisplatinum (R-DHAP) for the Treatment of Patients With Relapsed or Refractory DLBCL – Results From the Phase-II STORM Trial
Dokumenttyp:: Zeitschriftenaufsatz
Autor(en):: Witzens-Harig, Mathias; Viardot, Andreas; Keller, Ulrich; Wosniok, Julia; Deuster, Oliver; Klemmer, Jennifer; Geueke, Anne-Marie; Meißner, Julia; Ho, Anthony D.; Atta, Johannes; Marks, Reinhard; La Rosée, Paul; Buske, Christian; Dreyling, Martin H.; Hess, Georg
Zeitschriftentitel:: HemaSphere
Jahr:: 2021
Band / Volume:: 5
Heft / Issue:: 10
Seitenangaben Beitrag:: e636
Volltext / DOI:: doi:10.1097/hs9.0000000000000636
Verlag / Institution:: Ovid Technologies (Wolters Kluwer Health)
E-ISSN:: 2572-9241
Publikationsdatum:: 23.09.2021
BibTeX

Vorkommen: